AI
ByBiotech Licensing Soars to $137B in 2025 – China Now Leads the Licensing Race
The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to…
China Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?
China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…
Merck’s First Fully AI-Designed Oncology Drug: 2027 China Approval Nears or Hype Peaks?
Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…
Tsinghua’s Agent Hospital Pilots: World’s First AI Hospital or Closed Data Experiment?
Tsinghua University’s “world’s first AI Hospital” advanced public pilots February 28-March 2, 2026—deploying 42 AI agents across 300+…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1 global oncology leadership…
How Does Pfizer Transform Oncology Supremacy Into Sustainable Growth Beyond COVID Glory?
Pfizer engineers a “diversified oncology fortress” strategy featuring 108 pipeline candidates (one-third new molecular entities) across oncology, rare diseases, vaccines,…
